FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:446-456 July 31, 2003 Number 5 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Drüeke, T. B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Elevated calcium and phosphorus levels after therapy with injectable vitamin D for secondary hyperparathyroidism may accelerate vascular disease and hasten death in patients undergoing long-term hemodialysis. Paricalcitol, a new vitamin D analogue, appears to lessen the elevations in serum calcium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D.

Methods We conducted a historical cohort study to compare the 36-month survival rate among patients undergoing long-term hemodialysis who started to receive treatment with paricalcitol (29,021 patients) or calcitriol (38,378 patients) between 1999 and 2001. Crude and adjusted survival rates were calculated and stratified analyses were performed. A subgroup of 16,483 patients who switched regimens was also evaluated.

Results The mortality rate among patients receiving paricalcitol was 3417 per 19,031 person-years (0.180 per person-year), as compared with 6805 per 30,471 person-years (0.223 per person-year) among those receiving calcitriol (P<0.001). The difference in survival was significant at 12 months and increased with time (P<0.001). In the adjusted analysis, the mortality rate was 16 percent lower (95 percent confidence interval, 10 to 21 percent) among paricalcitol-treated patients than among calcitriol-treated patients. A significant survival benefit was evident in 28 of 42 strata examined, and in no stratum was calcitriol favored. At 12 months, calcium and phosphorus levels had increased by 6.7 and 11.9 percent, respectively, in the paricalcitol group, as compared with 8.2 and 13.9 percent, respectively, in the calcitriol group (P<0.001). The two-year survival rate among patients who switched from calcitriol to paricalcitol was 73 percent, as compared with 64 percent among those who switched from paricalcitol to calcitriol (P=0.04).

Conclusions Patients who receive paricalcitol while undergoing long-term hemodialysis appear to have a significant survival advantage over those who receive calcitriol. A prospective, randomized study is critical to confirm these findings.

Source Information

From Fresenius Medical Care North America, Lexington, Mass. (M.T., E.L., N.O., J.M.L.); and the Renal Unit, Massachusetts General Hospital, Harvard Medical School, Boston (M.W., R.T.).

Address reprint requests to Dr. Thadhani at Bullfinch 127, 55 Fruit St., Massachusetts General Hospital, Boston, MA 02114, or at thadhani.r{at}mgh.harvard.edu.

Full Text of this Article

Related Letters:

Paricalcitol, Calcitriol, and Survival of Patients Undergoing Hemodialysis
Colussi G., Kida Y., Ratnam S., Kaw D., Rao P., Wolf M., Teng M., Thadhani R.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:1971-1972, Nov 13, 2003. Correspondence

This article has been cited by other articles:

• Talmor-Barkan, Y., Rashid, G., Weintal, I., Green, J., Bernheim, J., Benchetrit, S. (2009). Low extracellular Ca2+: a mediator of endothelial inflammation. Nephrol Dial Transplant 24: 3306-3312 [Abstract] [Full Text]  
• Thadhani, R. (2009). Is Calcitriol Life-Protective for Patients with Chronic Kidney Disease?. J. Am. Soc. Nephrol. 20: 2285-2290 [Full Text]  
• Almirall, J., Vaqueiro, M., Bare, M. L., Anton, E. (2009). Association of low serum 25-hydroxyvitamin D levels and high arterial blood pressure in the elderly. Nephrol Dial Transplant 0: gfp470v1-gfp470 [Abstract] [Full Text]  
• Saliba, W., El-Haddad, B. (2009). Secondary Hyperparathyroidism: Pathophysiology and Treatment. J Am Board Fam Med 22: 574-581 [Abstract] [Full Text]  
• Jean, G., Terrat, J.-C., Vanel, T., Hurot, J.-M., Lorriaux, C., Mayor, B., Chazot, C. (2009). High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24: 2792-2796 [Abstract] [Full Text]  
• Kalantar-Zadeh, K., Kovesdy, C. P. (2009). Clinical Outcomes with Active versus Nutritional Vitamin D Compounds in Chronic Kidney Disease. CJASN 4: 1529-1539 [Abstract] [Full Text]  
• Eddington, H., Heaf, J. G. (2009). Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients. NDT Plus 2: 267-272 [Abstract] [Full Text]  
• Mizobuchi, M., Towler, D., Slatopolsky, E. (2009). Vascular Calcification: The Killer of Patients with Chronic Kidney Disease. J. Am. Soc. Nephrol. 20: 1453-1464 [Abstract] [Full Text]  
• Szeto, C.-C., Li, P. K.-T. (2009). The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism. NDT Plus 2: 205-212 [Abstract] [Full Text]  
• Covic, A., Kothawala, P., Bernal, M., Robbins, S., Chalian, A., Goldsmith, D. (2009). Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24: 1506-1523 [Abstract] [Full Text]  
• Palmer, S. C., Craig, J. C., Strippoli, G. F. M. (2009). Taking aim at targets. Nephrol Dial Transplant 24: 1358-1361 [Full Text]  
• Lee, P.-S., Sampath, K., Karumanchi, S. A., Tamez, H., Bhan, I., Isakova, T., Gutierrez, O. M., Wolf, M., Chang, Y., Stossel, T. P., Thadhani, R. (2009). Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality. J. Am. Soc. Nephrol. 20: 1140-1148 [Abstract] [Full Text]  
• Connor, A (2009). Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder. Postgrad. Med. J. 85: 274-279 [Abstract] [Full Text]  
• Chan, K. E., Lazarus, J. M., Thadhani, R., Hakim, R. M. (2009). Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients. J. Am. Soc. Nephrol. 20: 872-881 [Abstract] [Full Text]  
• Vervloet, M. G., Twisk, J. W. R. (2009). Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data. Nephrol Dial Transplant 24: 703-706 [Abstract] [Full Text]  
• Koleganova, N., Piecha, G., Ritz, E., Gross, M.-L. (2009). Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 24: 778-787 [Abstract] [Full Text]  
• Tentori, F., Albert, J. M., Young, E. W., Blayney, M. J., Robinson, B. M., Pisoni, R. L., Akiba, T., Greenwood, R. N., Kimata, N., Levin, N. W., Piera, L. M., Saran, R., Wolfe, R. A., Port, F. K. (2009). The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24: 963-972 [Abstract] [Full Text]  
• Isakova, T., Gutierrez, O. M., Chang, Y., Shah, A., Tamez, H., Smith, K., Thadhani, R., Wolf, M. (2009). Phosphorus Binders and Survival on Hemodialysis. J. Am. Soc. Nephrol. 20: 388-396 [Abstract] [Full Text]  
• Drueke, T. B., Ritz, E. (2009). Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives. CJASN 4: 234-241 [Abstract] [Full Text]  
• Tokmak, F., Quack, I., Schieren, G., Sellin, L., Rattensperger, D., Holland-Letz, T., Weiner, S. M., Rump, L. C. (2008). High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23: 4016-4020 [Abstract] [Full Text]  
• Noonan, W., Koch, K., Nakane, M., Ma, J., Dixon, D., Bolin, A., Reinhart, G. (2008). Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 23: 3824-3830 [Abstract] [Full Text]  
• Kovesdy, C. P., Anderson, J. E., Kalantar-Zadeh, K. (2008). Vitamin D Use and Mortality in Chronic Kidney Disease: Immortal Time Bias--Reply. Arch Intern Med 168: 2385-2386 [Full Text]  
• Jean, G., Terrat, J.-C., Vanel, T., Hurot, J.-M., Lorriaux, C., Mayor, B., Chazot, C. (2008). Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23: 3670-3676 [Abstract] [Full Text]  
• Fishbane, S., Shapiro, W. B., Corry, D. B., Vicks, S. L., Roppolo, M., Rappaport, K., Ling, X., Goodman, W. G., Turner, S., Charytan, C. (2008). Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone: The ACHIEVE Study Results. CJASN 3: 1718-1725 [Abstract] [Full Text]  
• Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., Demay, M. (2008). Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice. Endocr. Rev. 29: 726-776 [Abstract] [Full Text]  
• Wallis, D. E., Penckofer, S., Sizemore, G. W. (2008). The "Sunshine Deficit" and Cardiovascular Disease. Circulation 118: 1476-1485 [Full Text]  
• Al-Badr, W., Martin, K. J. (2008). Vitamin D and Kidney Disease. CJASN 3: 1555-1560 [Abstract] [Full Text]  
• Hsu, J. J., Tintut, Y., Demer, L. L. (2008). Vitamin D and Osteogenic Differentiation in the Artery Wall. CJASN 3: 1542-1547 [Abstract] [Full Text]  
• Danese, M. D., Belozeroff, V., Smirnakis, K., Rothman, K. J. (2008). Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients. CJASN 3: 1423-1429 [Abstract] [Full Text]  
• Ritz, E. (2008). Nephrology Potpourri. CJASN 3: 1253-1259 [Full Text]  
• Tan, X., Wen, X., Liu, Y. (2008). Paricalcitol Inhibits Renal Inflammation by Promoting Vitamin D Receptor-Mediated Sequestration of NF-{kappa}B Signaling. J. Am. Soc. Nephrol. 19: 1741-1752 [Abstract] [Full Text]  
• Gutierrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Juppner, H., Wolf, M. (2008). Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis. NEJM 359: 584-592 [Abstract] [Full Text]  
• Hsu, C.-y. (2008). FGF-23 and Outcomes Research -- When Physiology Meets Epidemiology. NEJM 359: 640-642 [Full Text]  
• Mathew, S., Lund, R. J., Chaudhary, L. R., Geurs, T., Hruska, K. A. (2008). Vitamin D Receptor Activators Can Protect against Vascular Calcification. J. Am. Soc. Nephrol. 19: 1509-1519 [Abstract] [Full Text]  
• Gutierrez, O. M., Tamez, H., Bhan, I., Zazra, J., Tonelli, M., Wolf, M., Januzzi, J. L., Chang, Y., Thadhani, R. (2008). N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentrations in Hemodialysis Patients: Prognostic Value of Baseline and Follow-up Measurements. Clin. Chem. 54: 1339-1348 [Abstract] [Full Text]  
• Wolf, M. (2008). Active Vitamin D and Survival. J. Am. Soc. Nephrol. 19: 1442-1443 [Full Text]  
• Alborzi, P., Patel, N. A., Peterson, C., Bills, J. E., Bekele, D. M., Bunaye, Z., Light, R. P., Agarwal, R. (2008). Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial. Hypertension 52: 249-255 [Abstract] [Full Text]  
• Weir, M. R. (2008). Is Activated Vitamin D Supplementation Renoprotective?. Hypertension 52: 211-212 [Full Text]  
• Wolf, M., Betancourt, J., Chang, Y., Shah, A., Teng, M., Tamez, H., Gutierrez, O., Camargo, C. A. Jr., Melamed, M., Norris, K., Stampfer, M. J., Powe, N. R., Thadhani, R. (2008). Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients. J. Am. Soc. Nephrol. 19: 1379-1388 [Abstract] [Full Text]  
• Dobnig, H., Pilz, S., Scharnagl, H., Renner, W., Seelhorst, U., Wellnitz, B., Kinkeldei, J., Boehm, B. O., Weihrauch, G., Maerz, W. (2008). Independent Association of Low Serum 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels With All-Cause and Cardiovascular Mortality. Arch Intern Med 168: 1340-1349 [Abstract] [Full Text]  
• Pai, A. B., Conner, T. A. (2008). Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D. Journal of Pharmacy Practice 21: 214-224 [Abstract]  
• Palmer, S., Strippoli, G. (2008). Reply: Vitamin D compounds in chronic kidney disease: change may be needed for good!. Nephrol Dial Transplant 23: 1789-1792 [Full Text]  
• Shroff, R., Egerton, M., Bridel, M., Shah, V., Donald, A. E., Cole, T. J., Hiorns, M. P., Deanfield, J. E., Rees, L. (2008). A Bimodal Association of Vitamin D Levels and Vascular Disease in Children on Dialysis. J. Am. Soc. Nephrol. 19: 1239-1246 [Abstract] [Full Text]  
• Raggi, P., Kleerekoper, M. (2008). Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease. CJASN 3: 836-843 [Abstract] [Full Text]  
• Kovesdy, C. P., Ahmadzadeh, S., Anderson, J. E., Kalantar-Zadeh, K. (2008). Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease. Arch Intern Med 168: 397-403 [Abstract] [Full Text]  
• Andress, D. L. (2008). Bone and Mineral Guidelines for Patients with Chronic Kidney Disease: A Call for Revision. CJASN 3: 179-183 [Abstract] [Full Text]  
• Bushinsky, D. A., Messa, P. (2008). Efficacy of Early Treatment with Calcimimetics in Combination with Reduced Doses of Vitamin D Sterols in Dialysis Patients. NDT Plus 1: i18-i23 [Abstract] [Full Text]  
• Palmer, S. C., McGregor, D. O., Macaskill, P., Craig, J. C., Elder, G. J., Strippoli, G. F.M. (2007). Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease. ANN INTERN MED 147: 840-853 [Abstract] [Full Text]  
• Tonelli, M. (2007). Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun. ANN INTERN MED 147: 880-881 [Full Text]  
• Saab, G., Whaley-Connell, A. T., Khanna, R., Sowers, J. R. (2007). Review: Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification. Ther Adv Cardiovasc Dis 1: 107-112 [Abstract]  
• Wu-Wong, J. R., Nakane, M., Ma, J., Ruan, X., Kroeger, P. E. (2007). Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. Am. J. Physiol. Renal Physiol. 293: F1592-F1604 [Abstract] [Full Text]  
• Bodyak, N., Ayus, J. C., Achinger, S., Shivalingappa, V., Ke, Q., Chen, Y.-S., Rigor, D. L., Stillman, I., Tamez, H., Kroeger, P. E., Wu-Wong, R. R., Karumanchi, S. A., Thadhani, R., Kang, P. M. (2007). Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl. Acad. Sci. USA 104: 16810-16815 [Abstract] [Full Text]  
• Lamb, E. J, Hodsman, A., van Schalkwyk, D., Ansell, D., Warwick, G. (2007). Serum calcium, phosphate, parathyroid hormone, albumin, aluminium and cholesterol achievement on replacement therapy (Chapter 9). Nephrol Dial Transplant 22: vii105-vii118 [Abstract] [Full Text]  
• Stubbs, J. R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., Quarles, L. D. (2007). Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice. J. Am. Soc. Nephrol. 18: 2116-2124 [Abstract] [Full Text]  
• Stompor, T. (2007). AN OVERVIEW OF THE PATHOPHYSIOLOGY OF VASCULAR CALCIFICATION IN CHRONIC KIDNEY DISEASE. pdi 27: S215-S222 [Abstract] [Full Text]  
• Martin, K. J., Gonzalez, E. A. (2007). Metabolic Bone Disease in Chronic Kidney Disease. J. Am. Soc. Nephrol. 18: 875-885 [Abstract] [Full Text]  
• Tan, X., Li, Y., Liu, Y. (2006). Paricalcitol Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy. J. Am. Soc. Nephrol. 17: 3382-3393 [Abstract] [Full Text]  
• Cannata-Andia, J. B., Rodriguez-Garcia, M., Carrillo-Lopez, N., Naves-Diaz, M., Diaz-Lopez, B. (2006). Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes. J. Am. Soc. Nephrol. 17: S267-S273 [Abstract] [Full Text]  
• Johnson, R. C., Leopold, J. A., Loscalzo, J. (2006). Vascular Calcification: Pathobiological Mechanisms and Clinical Implications. Circ. Res. 99: 1044-1059 [Abstract] [Full Text]  
• Liu, P.T., Stenger, S., Li, H., Wenzel, L., Tan, B.H., Krutzik, S.R., Ochoa, M.T., Schauber, J., Wu, K., Meinken, C., Kamen, D.L., Wagner, M., Bals, R., Steinmeyer, A., Zugel, U., Gallo, R.L., Eisenberg, D., Hewison, M., Hollis, B.W., Adams, J.S., Bloom, B.R., Modlin, R.L. (2006). Vitamin D3-Triggered Antimicrobial Response--Another Pleiotropic Effect beyond Mineral and Bone Metabolism: Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response. Science 311: 1770-1773, 2006. J. Am. Soc. Nephrol. 17: 2949-2953 [Full Text]  
• Dennis, V. C, Albertson, G. L (2006). Doxercalciferol Treatment of Secondary Hyperparathyroidism. The Annals of Pharmacotherapy 40: 1955-1965 [Abstract] [Full Text]  
• Reichel, H. (2006). Reply. Nephrol Dial Transplant 21: 2989-2990 [Full Text]  
• Bonne, J.-F., Mansour, J., Philippe Moriniere, I. S., Fournier, A. (2006). Current treatment options in secondary renal hyperparathyroidism. Nephrol Dial Transplant 21: 2987-2989 [Full Text]  
• Thadhani, R., Tonelli, M. (2006). Cohort Studies: Marching Forward. CJASN 1: 1117-1123 [Full Text]  
• Hudson, J. Q (2006). Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies. The Annals of Pharmacotherapy 40: 1584-1593 [Abstract] [Full Text]  
• Wu-Wong, J. R., Noonan, W., Ma, J., Dixon, D., Nakane, M., Bolin, A. L., Koch, K. A., Postl, S., Morgan, S. J., Reinhart, G. A. (2006). Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification. J. Pharmacol. Exp. Ther. 318: 90-98 [Abstract] [Full Text]  
• Zierold, C., Mings, J. A., Deluca, H. F. (2006). 19nor-1,25-Dihydroxyvitamin D2 Specifically Induces CYP3A9 in Rat Intestine More Strongly than 1,25-Dihydroxyvitamin D3 in Vivo and in Vitro. Mol. Pharmacol. 69: 1740-1747 [Abstract] [Full Text]  
• Schmitt, C. P., Odenwald, T., Ritz, E. (2006). Calcium, Calcium Regulatory Hormones, and Calcimimetics: Impact on Cardiovascular Mortality. J. Am. Soc. Nephrol. 17: S78-S80 [Abstract] [Full Text]  
• Chertow, G. M., Blumenthal, S., Turner, S., Roppolo, M., Stern, L., Chi, E. M., Reed, J., on behalf of the CONTROL Investigators, (2006). Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate. CJASN 1: 305-312 [Abstract] [Full Text]  
• Jindal, K., Chan, C. T., Deziel, C., Hirsch, D., Soroka, S. D., Tonelli, M., Culleton, B. F. (2006). CHAPTER 3: Mineral Metabolism. J. Am. Soc. Nephrol. 17: S11-S15 [Full Text]  
• Reichel, H. (2006). Current treatment options in secondary renal hyperparathyroidism. Nephrol Dial Transplant 21: 23-28 [Full Text]  
• Holick, M. F. (2005). The Vitamin D Epidemic and its Health Consequences. J. Nutr. 135: 2739S-2748S [Abstract] [Full Text]  
• Moe, S. M., Cunningham, J., Bommer, J., Adler, S., Rosansky, S. J., Urena-Torres, P., Albizem, M. B., Guo, M. D., Zani, V. J., Goodman, W. G., Sprague, S. M. (2005). Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20: 2186-2193 [Abstract] [Full Text]  
• Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernan, M. A., Camargo, C. A. Jr, Thadhani, R. (2005). Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study. J. Am. Soc. Nephrol. 16: 1115-1125 [Abstract] [Full Text]  
• Chen, S., Ni, X.-P., Humphreys, M. H., Gardner, D. G. (2005). 1,25 Dihydroxyvitamin D Amplifies Type A Natriuretic Peptide Receptor Expression and Activity in Target Cells. J. Am. Soc. Nephrol. 16: 329-339 [Abstract] [Full Text]  
• Norman, P.E., Powell, J.T. (2005). Vitamin D, Shedding Light on the Development of Disease in Peripheral Arteries. Arterioscler. Thromb. Vasc. Bio. 25: 39-46 [Abstract] [Full Text]  
• Xiang, W., Kong, J., Chen, S., Cao, L.-P., Qiao, G., Zheng, W., Liu, W., Li, X., Gardner, D. G., Li, Y. C. (2005). Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 288: E125-E132 [Abstract] [Full Text]  
• Sambrook, P. N., Chen, J. S., March, L. M., Cameron, I. D., Cumming, R. G., Lord, S. R., Schwarz, J., Seibel, M. J. (2004). Serum Parathyroid Hormone Is Associated with Increased Mortality Independent of 25-Hydroxy Vitamin D Status, Bone Mass, and Renal Function in the Frail and Very Old: A Cohort Study. J. Clin. Endocrinol. Metab. 89: 5477-5481 [Abstract] [Full Text]  
• Shoji, T. (2004). Reply. Nephrol Dial Transplant 19: 1661-1661 [Full Text]  
• Jorna, F. H., Tobe, T. J. M., Huisman, R. M., de Jong, P. E., Plukker, J. T. M., Stegeman, C. A. (2004). Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy. Nephrol Dial Transplant 19: 1168-1173 [Abstract] [Full Text]  
• Dobrez, D. G., Mathes, A., Amdahl, M., Marx, S. E., Melnick, J. Z., Sprague, S. M. (2004). Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19: 1174-1181 [Abstract] [Full Text]  
• Vattikuti, R., Towler, D. A. (2004). Osteogenic regulation of vascular calcification: an early perspective. Am. J. Physiol. Endocrinol. Metab. 286: E686-E696 [Abstract] [Full Text]  
• Curhan, G. (2004). Fooling the Parathyroid Gland -- Will There Be Health Benefits?. NEJM 350: 1565-1567 [Full Text]